A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Regorafenib (Primary)
- Indications Biliary cancer; Carcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms REGOMUNE
- 13 Jun 2019 Planned number of patients changed from 212 to 362.
- 13 Jun 2019 Planned End Date changed from 1 Apr 2021 to 1 May 2021.
- 13 Jun 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Nov 2020.